SEARCH · PubMed Health

Results for “Cross Protection”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 127 records · Page 7Linked to original sources

PubMed1981

Nature of the cross-protective antigen in subcellular vaccines of Streptococcus pneumoniae.

Studies have been carried out to investigate the nature of the antigen present in subcellular extracts of a rough strain of Streptococcus pneumoniae A662b which has been shown to confer protection in mice against challenge with smooth, virulent organisms of the homologous and heterologous serotypes. The finding that whole, heat-killed cells were also capable of immunizing mice against challenge with organisms of heterologous serotypes suggests that the immunogen is present on the surface of the rough pneumococcal cell. Ribosomes purified by sucrose gradient centrifugation were not protective, but material recovered in the pellet retained activity. Subcellular extracts prepared from spheroplasts with a partial absence of cell wall showed decreased protective capacity, and extracts prepared from wall-deficient protoplasts were not protective. Crude cell walls evidenced cross-serotype protection, but purified walls did not protect. These results are interpreted as suggesting that the active moiety in the subcellular vaccine is present on the surface of rough pneumococci and is either a wall antigen that must be part of a larger macromolecular complex to be immunogenic, or a substance associated with the cell wall that is present in crude, but not purified, cell wall fractions.

Animals↗

PubMed2001

Adaptive and cross-protective responses of Pseudomonas sp. DJ-12 to several aromatics and other stress shocks.

Pseudomonas sp. DJ-12 cells were subjected to mild treatments of stress such as exposure to biphenyl, 4-chlorobiphenyl (4CB), 4-hydroxybenzoate (4HBA), ethanol, and heat, and then were examined for production of stress-shock proteins and morphological changes. The adapted cells were then subjected to lethal stress conditions such as 200 mm 4CB, 100 mm biphenyl, 10 mm 4HBA, 20% ethanol, and 46 degrees C to examine crossly protective responses to the stresses. Several stress-shock proteins including DnaK and GroEL were newly synthesized in the adapted cells. Some of them were commonly produced by those stresses separately treated. The cells treated with these aromatic hydrocarbons showed destructive openings on the cell envelopes. On the other hand, those cells treated with ethanol or heat displayed irregular rod shapes with wrinkled surfaces. The adapted cells to each stress under sublethal conditions exhibited increased resistance to the same stress of lethal conditions. The cells adapted with 5 mm 4HBA showed greater protection for survival than those adapted by other stresses. In addition, those adapted cells showed increased resistance to other stresses as a cross-protection phenomenon. The cells adapted to 42 degrees C exhibited markedly increased resistance to the lethal stresses of 46 degrees C as well as to 20% ethanol.

Adaptation, Physiological↗

PubMed2000

Tobacco mosaic virus replicase-mediated cross-protection: contributions of RNA and protein-derived mechanisms.

Specific sequences of the tobacco mosaic virus (TMV) RNA-dependent RNA-polymerase (RdRp) gene were investigated for their ability to confer cross-protection. Nine overlapping segments ranging from 713 to 1070 nucleotides in length and covering the methyltransferase, helicase, and polymerase (POL) domains of the TMV RdRp open reading frame were systemically expressed in Nicotiana benthamiana using a potato X virus (PVX) vector [Chapman, S., Kavanagh, T., and Baulcombe, D. C. (1992). Plant J., 1, 549-557]. PVX-infected plants were subsequently challenge inoculated with 10 microg of wild-type TMV and monitored for TMV accumulation. Mock inoculated plants and plants preinfected with the unmodified PVX vector rapidly accumulated high levels of challenge virus. In contrast, plants preinfected with PVX vectors expressing segments of the TMV RdRp open reading frame displayed either high or low levels of protection. High protection levels were observed for PVX constructs expressing segments of the TMV POL domain, whereas low protection levels were observed for PVX constructs expressing segments covering the methyltransferase and helicase domains. Frameshift mutations that blocked protein expression from RdRp segments disrupted only the high levels of protection derived from POL segments and not the low levels derived from the other segments. However, all RdRp segments conferred similarly high levels of protection against a TMV construct with restricted local movement. Thus both RNA and protein sequences in conjunction with the speed of the infecting challenge virus can affect the protection derived from the TMV RdRp gene.

Frameshift Mutation↗

PubMed1984

Differences in cross-protection in rats immunized with the B subunits of cholera toxin and Escherichia coli heat-labile toxin.

Although cholera toxin (CT), Escherichia coli heat-labile toxin (LT), and their B subunits are known to be immunologically related, the ability of each to raise an antitoxin response that provides equally strong cross-protection against active challenge with pure heterologous toxin has not been examined previously. We immunized rats with pure preparations of the B subunits of human LT, porcine LT, and CT. Immunization with either of the LT B subunits raised greater than or equal to fourfold increases in specific mucosal immunoglobulin A antitoxin titers to homologous and heterologous LT and CT B subunits, thereby providing strong protection against active challenge in ligated ileal loops with all three respective holotoxins and with a viable LT-producing E. coli strain. In contrast, immunization with the CT B subunit raised a greater than or equal to fourfold increase in antitoxin titers only to itself and provided strong protection only against challenge with the CT holotoxin. Conjugation of the CT B subunit with the E. coli heat-stable toxin by the carbodiimide reaction yielded a cross-linked immunogen with equal antigenicity for both components; immunization with this conjugate raised greater than or equal to fourfold increases in antitoxin titers to both components, but it provided significant protection only against challenge with a viable heat-stable toxin-producing E. coli strain and not to an LT-producing E. coli strain. These observations indicate that immunization with the LT B subunits raises a heterologous antitoxin response that extends to the CT B subunit, thereby providing equally strong protection against LT and CT; however, immunization with the CT B subunit raises principally a homologous antitoxin response, so that this immunogen provides strong protection only against CT.

Animals↗

PubMed1977

Demonstration of cross-protection between Pasteurella multocida type A and Pasteurella haemolytica, serotype 1.

Mice immunized with the potassium thiocyanate extract of Pasteurella haemolytica, serotype 1, were found to resist a challenge infection of P. multocida type A, thus demonstrating cross-protection. This finding was further supported by the finding that an antiserum directed against the potassium thiocyanate extract of P. haemolytica was bactericidal to P. multocida and vice versa.

Animals↗

PubMed1986

Immunity to tapeworms: intraspecific cross-protective interactions between Hymenolepis citelli, H. diminuta and H. microstoma in mice.

Interactions between tapeworm species in a single host offer intriguing opportunities for immunological studies that attempt to identify the mechanism(s) underlying protection against cestode infections. Mice that are immunized against Hymenolepis citelli infections were shown to be refractory to subsequent H. diminuta challenge infections. The reciprocity of the response was also demonstrated, although the protection recorded for H. diminuta when mice are sensitized with H. citelli is weaker than that observed when mice are primed with H. diminuta against H. citelli challenge. H. citelli was also shown to be expelled simultaneously during the rejection phase of H. diminuta in concurrent infections, indicating the susceptibility of the former tapeworm to the rejection mechanism initiated by the latter. H. microstoma-immunized mice were shown to be strongly protected against heterologous H. citelli challenge. However, mice primed against H. citelli were not as strongly protected against H. microstoma challenge infections: a statistically significant protection was obtained only after a 12-cysticercoid H. citelli primary infection, although a 6-cyst infection did stunt the growth of H. microstoma challenge worms. It is presently suggested that the cross-protective responses observed in the study between H. citelli, H. diminuta and H. microstoma may have emanated from a specific immunological cross-reactivity due to the sharing of similar immunogens.

Animals↗

PubMed1989

Cross-protection against microvariants of influenza virus type B by vaccinia viruses expressing haemagglutinins from egg- or MDCK cell-derived subpopulations of influenza virus type B/England/222/82.

B/Singapore/222/79-like influenza viruses isolated from three patients during the winter of 1981 to 1982 and cultured in either embryonated hens' eggs or MDCK cells were studied. Sequence analysis indicated that the haemagglutinin (HA) genes of the six virus preparations contained at least four distinct HA1 sequences which differed by up to six amino acids. Only one pair of viruses had amino acid differences between the egg- and MDCK cell-derived viral subpopulations and this change did not affect a glycosylation site. Mice infected with previously described recombinant vaccinia viruses expressing either the egg- or MDCK cell-derived HA of B/England/222/82 developed neutralizing antibodies against all of the 1982 type B viruses and were protected against intranasal challenge with these viruses. Therefore, in this model system, the minor sequence variation between the HAs of egg- and MDCK cell-derived influenza B/England/222/82 virus had no detectable effect on the induction of cross-protection.

Amino Acid Sequence↗

PubMed1994

Coronavirus infections in the laboratory rat: degree of cross protection following immunization with a heterologous strain.

One hundred and twenty-one specific pathogen-free male Wistar rats eight to ten weeks of age were used to evaluate the efficacy of Parker's rat coronavirus (PRC) in affording cross protection on subsequent challenge with virulent sialodacryoadenitis (SDA) virus. Sixty-two animals were inoculated intranasally on day 0 and 21 days later with approximately 10(2) median tissue culture infective doses (TCID50) of the tenth passage of PRC replicated in L-2 cells. Animals were selected at random postvaccination to evaluate the safety and efficacy of PRC by histopathology, immunohistochemistry and serology. At three and six months postvaccination (PV), vaccinated and seronegative control rats were inoculated intranasally with approximately 10(3) TCID50 doses of virulent SDA virus. Challenged rats were then killed at 6, 10 and 14 days postchallenge and necropsied. Evaluations were based on lesion indices in lacrimal and salivary glands and respiratory tract, the presence of viral antigen by immunohistochemistry, and antibody response. Lesions were observed in rats killed PV, but in general, they were significantly reduced compared with those present in seronegative animals post-exposure to virulent SDA virus (p < or = 0.05). However, they were still considered to be an unacceptable level for a routine vaccination procedure. Potvaccination antibody titers to rat coronavirus were evident in all animals tested at three or six months prior to challenge with SDA virus.(ABSTRACT TRUNCATED AT 250 WORDS)

Administration, Intranasal↗

PubMed1978

A comparison of cross protection between BCG, Hammondia hammondi, Besnoitia jellisoni and Toxoplasma gondii in hamsters.

The effect of pretreatment with BCG strain of Mycobacterium tuberculosis or Hammondia hammondi 21 days before challenge with lethal doses of T oxoplasma gondii and Besnoitia jellisoni was studied in hamsters. The results indicated that the intracardial administration of BCG provided no protection against either T. gondii or B. jellisoni. The hamsters immunized with H. hammondi survived challenge with 10(4) lethal doses of T. gondii but only 1 lethal dose with B. jellisoni, indicating strong cross protection between H. hammondi and T. gondii and only a marginal one between H. hammondi and B. jellisoni.

Animals↗

PubMed1972

The mechanism of cross-protection afforded by dengue virus against West Nile virus in hamsters.

The protection afforded by similar concentrations of different dengue virus serotypes against a subsequent challenge of West Nile virus was studied in hamsters. The New Guinea C strain of dengue 2 virus gave the best protection. It was found that the anamnestic neutralizing antibody response induced by the challenge West Nile virus against West Nile virus in hamsters, previously immunized with dengue 2 virus, might play a major role in the cross-protection observed in this system.

Animals↗

PubMed2000

Identification of group B streptococcal Sip protein, which elicits cross-protective immunity.

A protein of group B streptococci (GBS), named Sip for surface immunogenic protein, which is distinct from previously described surface proteins, was identified after immunological screening of a genomic library. Immunoblots using a Sip-specific monoclonal antibody indicated that a protein band with an approximate molecular mass of 53 kDa which did not vary in size was present in every GBS strain tested. Representatives of all nine GBS serotypes were included in the panel of strains. Cloning and sequencing of the sip gene revealed an open reading frame of 1,305 nucleotides coding for a polypeptide of 434 amino acid residues, with a calculated pI of 6. 84 and molecular mass of 45.5 kDa. Comparison of the nucleotide sequences from six different strains confirmed with 98% identity that the sip gene is highly conserved among GBS isolates. N-terminal amino acid sequencing also indicated the presence of a 25-amino-acid signal peptide which is cleaved in the mature protein. More importantly, immunization with the recombinant Sip protein efficiently protected CD-1 mice against deadly challenges with six GBS strains of serotypes Ia/c, Ib, II/R, III, V, and VI. The data presented in this study suggest that this highly conserved protein induces cross-protective immunity against GBS infections and emphasize its potential as a universal vaccine candidate.

Amino Acid Sequence↗

PubMed1981

Prevention of tumors in rats by cross-protective immunization.

F344 inbred were repeatedly immunized (days 0, 28, and 42) with normal syngeneic or allogeneic rat tissues or transplantable syngeneic or allogeneic rat tumors (some of which were virus producing). Immunized rats were challenged by sc injection of 10(5) or 10(6) syngeneic rat tumor cells from either of two different tumor lines. Successful cross-protective immunization prevented tumor development in rats that were challenged at 100-1,000 times the 50% tumor dose. The protection was essentially lifelong and complete in that no tumors appeared up to 200 days post challenge in some experiments. To be successful, the tumor cell vaccines had to express a complement-fixing cross-reacting antigen detected with sera from rats bearing any of several different tumors and to be able to induce a spontaneously regressing tumor in the host.

Animals↗

PubMed1997

Cross-protection by anti-core glycolipid antibodies: evidence from animal experiments.

The ability of antibodies against the core glycolipid (CGL) of endotoxin to protect experimentally infected animals against death from Gram-negative sepsis is reviewed. The limitations and confounding factors inherent to animal models of sepsis are also briefly discussed. This review considers 30 studies in mice and 12 in other animal species that investigated protection against heterologous challenge by passive immunization with anti-CGL antibodies. In 28 (67%) of the reviewed studies antibodies were found to be protective, either prophylactically (n = 17) or therapeutically (n = 11). With the possible exception of the type of antibody preparation that was used (monoclonal versus polyclonal antibodies), none of the many differences in the experimental protocols were clearly correlated with success. Convincing proof is still lacking for any of the hypothetical mechanisms of protection by anti-CGL antibodies. Moreover, the evidence that protection by these antibodies is attributable to their anti-CGL specificity is poor. The available data raise serious questions about the validity of the concept underlying the search for broadly cross-protective antibodies raised against the core region of endotoxin. However, continuing research suggests that endotoxin still is a valid target in devising new adjunctive treatment strategies to improve the outcome of serious Gram-negative infections.

Animals↗

PubMed1999

Human anti-Pseudomonas aeruginosa outer membrane proteins IgG cross-protective against infection with heterologous immunotype strains of P. aeruginosa.

In order to develop an effective means to treat and prevent Pseudomonas aeruginosa infections, we have purified P. aeruginosa outer membrane protein (Oprs)-specific human IgG antibody using a large-scale affinity column. In this study, we investigated the cross-protective activity of the purified anti-Oprs IgG against various immunotype strains of P. aeruginosa. The anti-Oprs IgG reacted with Oprs isolated from seven Fisher-Devlin immunotype strains of P. aeruginosa and was able to promote opsonophagocytic killing of all seven immunotype strains by human phagocytic cells. Administration of 500 microg anti-Oprs IgG to mice raised the LD50 of the P. aeruginosa strains by 8-250-fold, indicating the protective capacity against heterologous P. aeruginosa strains as well as homologous strains. In contrast, despite high titers against P. (aeruginosa Oprs, total serum IgG isolated from burn patient sera was no better than normal serum IgG in protecting mice from infection with P. aeruginosa. These data demonstrate that the affinity-purified human anti-Oprs IgG could afford protection against heterologous immunotype P. aeruginosa strains and provide a rationale to use anti-Oprs IgG as an adjunct for treatment of P. aeruginosa infections in humans.

Animals↗

PubMed1977

Cross-protective immunity to Gram-negative bacilli: studies with core glycolipid of Salmonella minnesota and antigens of Streptococcus pneumoniae.

Two immunoprophylactic approaches to the control of infections caused by gramnegative bacilli were evaluated by study of experimental infections in animals. The core glycolipid antigen derived from the Re mutant of Salmonella minnesota R595 is shared by virtually all enteric bacteria, and immunization with this endotoxin protects against the hemodynamic sequelae of bacterial infection and pyrexia without enhancing intravascular clearance of bacteria. The degree of protection afforded by active and passive immunization with core glycolipid was significantly less than that conferred by type-specific immunization. Escherichia coli and Klebsiella pneumoniae share capsular antigens with some strains of Streptococcus pneumoniae; by the mechanism of enhanced opsonization, antibodies to S. pneumoniae may cross-protect against infection with E. coli or K. pneumoniae.

Animals↗

PubMed1991

[The Borrelia of ornithodoros in tropical Africa: value and limits of cross protection tests in the mouse].

The identification of Borrelia strains isolated from ticks or relapsing fever patients is not easy. Seizing the opportunity of recent isolation of such strains from Western Africa, we tried to evaluate the interest and the limits of a method classically proposed for that aim; cross protection test in mouse. This technique is proving rather difficult to perform because of different technical reasons; the results are critical to read. In some cases, these results seem undeniable, but the observed differences in protection levels are often weak, inconstant, insufficiently reliable to constitute a diagnostic tool. So it appears important to develop other identification methods, based on molecular analysis of Borrelia DNA, which will be more subtle and more specific.

Africa, Western↗

PubMed1972

Cross-protective antigens of Neisseria meningitidis obtained from Slaterus group Y.

An extraction of the cells of Neisseria meningitidis serogroup Y with an aqueous solution of calcium choride (0.9 m) has been shown to solubilize a number of antigens. By immunodiffusion, this mixture of antigens has been shown to react with its group-specific antiserum and also to cross-react with a number of other group-specific antisera. The cross-reacting antigen appears to be an antigen common to a number of other serogroups of meningococci, and there is some evidence that it is protein in nature. It has been demonstrated further that the calcium chloride extract contains a strong cross-protective antigen, as shown by its ability to provide good, active immunity in mice to both the homologous and heterologous serogroups of meningococci.

Animals↗

PubMed1995

Cross-protection of mice against a global spectrum of rabies virus variants.

Rabies, a continuing worldwide problem, kills tens of thousands of people and millions of animals each year. The problem is most severe in developing countries, where cell culture-derived vaccines are unaffordable and the available nervous tissue-derived vaccines are often of questionable immunogenicity and may produce neurological complications. To determine the feasibility of developing a vaccine with worldwide applicability, we investigated whether recombinant vaccinia viruses expressing either the glycoprotein (G), the nucleoprotein (N), or both the G and N (GN) of the challenge virus strain (CVS) of rabies virus would cross-protect mice against 17 rabies virus isolates representing the spectrum of rabies virus variants found worldwide. The results were compared with the commercially available human diploid cell vaccine (HDCV). Among mice injected with any of the 17 viruses, > or = 95% were protected by vaccination with recombinant viruses expressing G or GN, and > or = 85% of the mice were protected by the HDCV. The recombinant virus expressing N was less protective, protecting against only 11 of the 17 viruses. Antibody prepared against the G of the strains used in the vaccines neutralized all 17 viruses, and sera from mice infected with any one virus variant cross-neutralized all of the other viruses. Thus, no antigenic differences that would potentiate vaccine failures were identified. These studies suggest that a single rabies virus strain or its G would protect globally against wild-type rabies viruses.

Animals↗